BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee AWM, Lee VHF, Ng WT, Strojan P, Saba NF, Rinaldo A, Willems SM, Rodrigo JP, Forastiere AA, Ferlito A. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer 2021;153:109-22. [PMID: 34153713 DOI: 10.1016/j.ejca.2021.05.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee VH, Adham M, Ben Kridis W, Bossi P, Chen M, Chitapanarux I, Gregoire V, Hao SP, Ho C, Ho GF, Kannarunimit D, Kwong DL, Lam K, Lam WKJ, Le Q, Lee AW, Lee NY, Leung T, Licitra L, Lim DW, Lin J, Loh KS, Lou P, Machiels J, Mai H, Mesía R, Ng W, Ngan RK, Tay JK, Tsang RK, Tong C, Wang H, Wee JT. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. The Lancet Oncology 2022;23:e544-e551. [DOI: 10.1016/s1470-2045(22)00505-8] [Reference Citation Analysis]
2 Liu Y, Qiu Y, Li X, Huang D, Zou G, Fan S, Shi L, Jiang S, Zhou Q, Feng R, Guo Y, Li X, Zhu Y, Xiang B, Zeng Z, Xiong W, Li G, Zhang W. The prognostic value of the seventh edition of the AJCC staging system for nasopharyngeal carcinoma in China.. [DOI: 10.21203/rs.3.rs-2305971/v1] [Reference Citation Analysis]
3 Xu Y, Chen K, Liang Z, Zhu X. Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis. Eur Arch Otorhinolaryngol 2022. [DOI: 10.1007/s00405-022-07726-8] [Reference Citation Analysis]
4 Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J, Chen X, Qu S, Lin L, Huang J, Wu H, Lu Y, Wang W, Hu C, He X, Yu Z, Liu X, Xie B, Liu A, Hu G, Jing S, Zhang Q, Guo R, Li Q, Hong J, Jin F, Meng J, Shi J, Wang P, Cui J, Yang K, Zhang X, Li X, Shen L, He Y, Zhai L, Sun X, Ge J, Qing Y, Zong D. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 study. The Lancet Regional Health - Western Pacific 2022. [DOI: 10.1016/j.lanwpc.2022.100617] [Reference Citation Analysis]
5 Xue F, Ou D, Ou X, Zhou X, Hu C, He X. Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2022;134:106139. [PMID: 36179488 DOI: 10.1016/j.oraloncology.2022.106139] [Reference Citation Analysis]
6 Zong J, Ji P, Lin C, Zhang R, Chen Y, Lu Q, Peng X, Pan J, Lin S. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma. Oral Oncol 2022;131:105972. [PMID: 35728415 DOI: 10.1016/j.oraloncology.2022.105972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Xiao XT, Wu YS, Chen YP, Liu X, Guo R, Tang LL, Ma J, Li WF. Patterns and prognosis of regional recurrence in nasopharyngeal carcinoma after intensity-modulated radiotherapy. Cancer Med 2022. [PMID: 35822664 DOI: 10.1002/cam4.5020] [Reference Citation Analysis]
8 Xu Y, Chen K, Liang Z, Zhu X. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma. Front Oncol 2022;12:843675. [DOI: 10.3389/fonc.2022.843675] [Reference Citation Analysis]
9 Aulakh SS, Silverman DA, Young K, Dennis SK, Birkeland AC. The Promise of Circulating Tumor DNA in Head and Neck Cancer. Cancers (Basel) 2022;14:2968. [PMID: 35740633 DOI: 10.3390/cancers14122968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Islam KA, Chow LK, Kam NW, Wang Y, Chiang CL, Choi HC, Xia Y, Lee AW, Ng WT, Dai W. Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature. Cancers 2022;14:2122. [DOI: 10.3390/cancers14092122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ng WT, Chua MLK, Lee AWM. Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis? J Clin Oncol 2022;:JCO2200099. [PMID: 35213233 DOI: 10.1200/JCO.22.00099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Liang ZG, Zhang F, Li Y, Li L, Qu S, Su F, Yu BB, Guan Y, Han L, Li KG, Zhu XD. The Integration of the Pre-Treatment Neutrophil-to-Lymphocyte Ratio in the Eighth Edition of the AJCC Staging System for Nasopharynx Cancer. Front Oncol 2021;11:724467. [PMID: 34858812 DOI: 10.3389/fonc.2021.724467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xu J, Wang J, Bian X, Zhu JQ, Tie CW, Liu X, Zhou Z, Ni XG, Qian D. Deep Learning for nasopharyngeal Carcinoma Identification Using Both White Light and Narrow-Band Imaging Endoscopy. Laryngoscope 2021. [PMID: 34622964 DOI: 10.1002/lary.29894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]